Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story
- PMID: 31514446
- PMCID: PMC6770829
- DOI: 10.3390/cancers11091346
Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story
Abstract
The purine nucleotides ATP and GTP are essential precursors to DNA and RNA synthesis and fundamental for energy metabolism. Although de novo purine nucleotide biosynthesis is increased in highly proliferating cells, such as malignant tumors, it is not clear if this is merely a secondary manifestation of increased cell proliferation. Suggestive of a direct causative effect includes evidence that, in some cancer types, the rate-limiting enzyme in de novo GTP biosynthesis, inosine monophosphate dehydrogenase (IMPDH), is upregulated and that the IMPDH inhibitor, mycophenolic acid (MPA), possesses anti-tumor activity. However, historically, enthusiasm for employing IMPDH inhibitors in cancer treatment has been mitigated by their adverse effects at high treatment doses and variable response. Recent advances in our understanding of the mechanistic role of IMPDH in tumorigenesis and cancer progression, as well as the development of IMPDH inhibitors with selective actions on GTP synthesis, have prompted a reappraisal of targeting this enzyme for anti-cancer treatment. In this review, we summarize the history of IMPDH inhibitors, the development of new inhibitors as anti-cancer drugs, and future directions and strategies to overcome existing challenges.
Keywords: GTP; IMPDH; IMPDH inhibitors; anti-tumor; mycophenolic acid; purine synthesis.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures










Similar articles
-
Induction of IMPDH-Based Cytoophidia by a Probable IMP-Dependent ARL13B-IMPDH Interaction.Biochemistry (Mosc). 2024 Dec;89(12):2287-2291. doi: 10.1134/S0006297924120162. Biochemistry (Mosc). 2024. PMID: 39865040
-
Inosine-5'-monophosphate dehydrogenase is required for mitogenic competence of transformed pancreatic beta cells.Endocrinology. 2001 Jan;142(1):193-204. doi: 10.1210/endo.142.1.7869. Endocrinology. 2001. PMID: 11145582
-
Live-cell analysis of IMPDH protein levels during yeast colony growth provides insights into the regulation of GTP synthesis.mBio. 2024 Aug 14;15(8):e0102124. doi: 10.1128/mbio.01021-24. Epub 2024 Jun 28. mBio. 2024. PMID: 38940616 Free PMC article.
-
Mechanism of action of mycophenolate mofetil.Ther Drug Monit. 1995 Dec;17(6):681-4. doi: 10.1097/00007691-199512000-00023. Ther Drug Monit. 1995. PMID: 8588241 Review.
-
The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors.Immunopharmacology. 2000 May;47(2-3):163-84. doi: 10.1016/s0162-3109(00)00193-4. Immunopharmacology. 2000. PMID: 10878288 Review.
Cited by
-
Repurposing immunosuppressants for antileukemia therapy.EMBO Mol Med. 2023 Jan 11;15(1):e17042. doi: 10.15252/emmm.202217042. Epub 2022 Dec 1. EMBO Mol Med. 2023. PMID: 36453114 Free PMC article.
-
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review.Dermatol Ther (Heidelb). 2022 Apr;12(4):835-860. doi: 10.1007/s13555-022-00713-1. Epub 2022 Apr 5. Dermatol Ther (Heidelb). 2022. PMID: 35381976 Free PMC article. Review.
-
Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors.Cancers (Basel). 2021 Jul 24;13(15):3727. doi: 10.3390/cancers13153727. Cancers (Basel). 2021. PMID: 34359627 Free PMC article.
-
Metabolic Reprogramming and Vulnerabilities in Cancer.Cancers (Basel). 2019 Dec 30;12(1):90. doi: 10.3390/cancers12010090. Cancers (Basel). 2019. PMID: 31905922 Free PMC article.
-
Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial.BMC Cancer. 2020 Mar 30;20(1):268. doi: 10.1186/s12885-020-06751-2. BMC Cancer. 2020. PMID: 32228535 Free PMC article.
References
-
- Kofuji S., Hirayama A., Eberhardt A.O., Kawaguchi R., Sugiura Y., Sampetrean O., Ikeda Y., Warren M., Sakamoto N., Kitahara S., et al. IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. Nat. Cell Biol. 2019;21:1003–1014. doi: 10.1038/s41556-019-0363-9. - DOI - PMC - PubMed
-
- Collart F.R., Chubb C.B., Mirkin B.L., Huberman E. Increased inosine-5′-phosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines. Cancer Res. 1992;52:5826–5828. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources